ADHERENCE TO TREAT-TO-TARGET APPROACH IN A RHEUMATOID ARTHRITIS COHORT: RETROSPECTIVE ANALYSIS FROM 3 YEARS OF REAL-LIFE EXPERIENCE IN A REFRACTORY CLINIC

被引：0
|
作者：
Maranini, B. [1 ]
Silvagni, E. [1 ]
Venturelli, V. [1 ]
Piovani, A. [2 ]
Zagnoni, E. [1 ]
Govoni, M. [1 ]
机构：
[1] Univ Ferrara, Dept Med Sci, Ferrara, Italy
[2] Univ Bologna, Dept Phys Augusto Righi, Bologna, Italy
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Treat to target; Rheumatoid arthritis; bDMARD;
D O I：
10.1136/annrheumdis-2023-eular.2829
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0223
引用
收藏
页码：1295 / 1296
页数：2
相关论文
共 50 条
  • [41] What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis
    Messelink, Marianne A.
    den Broeder, Alfons A.
    Marinelli, Florine E.
    Michgels, Edwin
    Verschueren, P.
    Aletaha, Daniel
    Tekstra, Janneke
    Welsing, Paco M. J.
    RMD OPEN, 2023, 9 (02):
  • [42] Real-World Treat-to-Target Strategy in Psoriatic Arthritis: Baseline Characteristics from the MONITOR-PsA Cohort
    James, Lija
    Saeedi, Elnaz
    Letarouilly, Jean-Guillaume
    Gullick, Nicola
    Francis, Anne
    Jadon, Deepak
    Tillett, William
    Sinomati, Yvonne
    Tucker, Laura
    Mian, Nadia
    Rombach, Ines
    Marian, Ioana
    Massa, Maria Sofia
    Coates, Laura
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2953 - 2956
  • [43] TREAT TO TARGET AND THE REAL LIFE EXPERIENCE - DATA FROM A COHORT OF RHEUMATOID ARTHRTIS PATIENTS IN SOUTH EAST ROMANIA (CONSTANTA COUNTY)
    Suta, V. C.
    Andronache, I-T.
    Suta, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1162 - 1162
  • [44] The Advantage of Tight Control and Treat-to-Target in New-onset Rheumatoid Arthritis Patients in Daily Rheumatology Practice: Results from a Contemporary University Clinic Inception Cohort
    Pajalic, Katarina Friberger
    Einarsson, Jon Thorkel
    Bengtsson, Caroline
    Landgren, Ellen
    Mogard, Elisabeth
    Roseman, Carmen
    Wallman, Johan Karlsson
    Lindqvist, Elisabet
    Olofsson, Tor
    Kapetanovic, Meliha
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2625 - 2627
  • [45] The Safety and Effectiveness of Infliximab Biosimilar in Managing Rheumatoid Arthritis: A Real-Life Experience from Jordan
    Alawneh, Khaldoon
    Al-Mistarehi, Abdel-Hameed
    Qandeel, Ali
    Jaber, Ruba
    Alomari, Safwan
    Kheirallah, Khalid A.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2022, 2022
  • [46] Unmet Treat-to-Target Goals with Available Targeted Immunomodulators in the Management of Rheumatoid Arthritis: Real World Evidence from the Corrona Registry
    Pappas, Dimitrios A.
    Tundia, Namita
    Shan, Ying
    Litman, Heather J.
    Kremer, Joel
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [47] Efficacy and safety of tocilizumab in refractory rheumatoid arthritis: a real life cohort from a single centre
    Addimanda, O.
    Possemato, N.
    Macchioni, P.
    Salvarani, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (04) : 460 - 464
  • [48] Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience
    Evangelatos, Gerasimos
    Fragoulis, George E.
    Klavdianou, Kalliopi
    Moschopoulou, Melina
    Vassilopoulos, Dimitrios
    Iliopoulos, Alexios
    RHEUMATOLOGY, 2021, 60 (05) : 2375 - 2382
  • [49] Analysis of potential determinants for a treat-to-target strategy in psoriatic arthritis patients from a real-world setting
    Lubrano, E.
    Scriffignano, S.
    De Socio, A.
    Perrotta, F. M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (03) : 512 - 512
  • [50] Treat-to-Target in Rheumatoid Arthritis: What Level of Treatment Response Is Necessary By 3 Months in Order to Achieve the Treatment Target By 6 Months? Results from the Real Life NOR-DMARD Study
    Norvang, Vibeke
    Olsen, Inge C.
    Sexton, Joseph
    Kristianslund, Eirik K.
    Uhlig, Till
    Kvien, Tore
    Aletaha, Daniel
    Smolen, Josef S.
    Haavardsholm, Espen A.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
12345